588729-97-9

Upstream product

• 38185-55-6 5-bromo-3-chloropyridin-2-ylamine 
• 381233-96-1 2-amino-3-iodo-5-bromopyridine 
• 532-55-8 Benzoyl isothiocyanate 
• 98-88-4 benzoyl chloride 
• 588729-96-8 N-benzoyl-N'-(5-bromo-3-chloro-2-pyridyl)thiourea 

Downstream Products

• 588730-01-2 N-(6-bromo-thiazolo[5,4-b]pyridine-2-yl)-benzamide 
• 857970-06-0 2-amino-6-bromo[1,3]thiazolo[4,5-b]pyridine 
• 960535-44-8 6-bromo-2-chlorothiazolo[4,5-b]pyridine 
• 588730-02-3 N-(6-phenyl-thiazol[5,4-b]pyridin-2-yl)-benzamide 
• 588729-98-0 N-(6-phenyl-thiazolo[4,5-b]pyridin-2-yl)-benzamide 

Relevant academic research and scientific papers

1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY

The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

Oxidative cyclization of N-methyl- and N-benzoylpyridylthioureas. Preparation of new thiazolo[4,5-b] and [5,4-b]pyridine derivatives

Cyclization of N-methyl- and N-benzoylpyridylthioureas, prepared from the corresponding aminopyridines, has been realized using various conditions. With bromine in acetic acid or potassium ferricyanide, the cyclization occurred on the nitrogen of the pyridine ring and pyridinium salts or 1,2,4-thiadiazolo[2,3-a]pyridylidene systems were obtained. On the other hand, treatment of the thioureas with sodium methoxide in N-methylpyrrolidinone (NMP) led to formation of thiazolo[4,5-b] and [5,4-b]pyridines, which are interesting targets for biological evaluation.